REG - Ergomed plc - Board and Management Changes <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

13/04/2017 07:01

RNS Number : 3757C
Ergomed plc
13 April 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
Board and Management Changes
London, UK - 13 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces Board and management changes.
Neil Clark will step down as a Director of Ergomed plc with effect from 16 April 2017. Neil is leaving to become Chief Executive Officer of Destiny Pharma Limited, a company focused on the discovery, development and commercialisation of novel antimicrobials. Neil will remain on the Board of our subsidiary, PrimeVigilance, as a non-executive director and a consultant during a transition period. 
Dr. Jan Petracek will step into the role of Chief Executive Officer of PrimeVigilance. Jan joined Ergomed in November 2016 as CEO of European PharmInvent Services s.r.o. following its acquisition and subsequent integration into PrimeVigilance. 
Dr. Miroslav Reljanovic, Chief Executive Officer of Ergomed, said:
"I would like to give my sincere thanks to Neil for his eight years' service to Ergomed. He has helped the Company transition from a private company through the IPO process in 2014 and latterly, overseen a period of strong growth in PrimeVigilance. I wish him all the best in the next stage of his career. 
"We are fortunate to have in the wings a replacement CEO of the calibre of Dr. Jan Petracek. As founder of PharmInvent and former regulator at EMA, his unique combination of entrepreneurship and specialist pharmacovigilance expertise will serve to drive forward our pharmacoviglance businesses." 
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Miroslav Reljanovic (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer,)



Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)



Stifel Nicolaus Europe Limited
Tel: +44 (0) 20 7710 7600
Jonathan Senior / Ben Maddison (Joint Broker) 



FTI Consulting - for UK enquiries
Tel: +44 (0) 20 3727 1000
Simon Conway / Mo Noonan / Natalie Garland-Collins



MC-Services - for Continental European enquiries
Tel: +49 211 52925222
Anne Hennecke

About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
BOAEASLAFLLXEFF